Biography: Rajiv Agarwal, MD

Rajiv Agarwal, MD
  • Professor of Medicine
  • Indiana University School of Medicine & VA Medical Center
  • Indianapolis, IN

Rajiv Agarwal, MD is a tenured Professor of Medicine at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Agarwal earned his medical degree from the All India Institute of Medical Sciences in New Delhi, India. After completing his residency in Internal Medicine at the same institution he completed a Nephrology fellowship at the University of Texas Southwestern Medical Center at Dallas. In July 1997, he joined Indiana University as Clinical Assistant Professor and within 10 years was promoted to the rank of full Professor. Dr. Agarwal has published about 250 original papers and reviews in Nephrology. He has been invited to lecture on numerous occasions by such national societies as the National Kidney Foundation, American Society of Nephrology, International Society of Nephrology, European Dialysis and Transplant Association, and the American Heart Association. Dr. Agarwal has received the Indiana University Trustee's teaching award and the Young Scholar Award of the American Society of Hypertension. He serves on the Editorial Board of Kidney International, Clinical Journal of the American Society of Nephrology, Hypertension, and Seminars in Dialysis. He also serves as an Editor for Nephrology Dialysis Transplantation, American Journal of Nephrology, and Journal of the American Society of Hypertension. He also served as an Associate Editor of NephSAP (Nephrology Self-Assessment Program) for 6 years.

Dr. Agarwal is an internationally recognized leader in the area of clinical and translational research in nephrology. He was among the first to demonstrate the effect of add-on angiotensin receptor blockade on cytokine production and oxidative stress in patients with chronic kidney disease (CKD). He has developed a technique for measuring oxidative stress biomarkers using high-performance liquid chromatography (HPLC) and applied this method to demonstrate generations of oxidative stress with intravenous iron in patients with CKD. He was the first to describe the antiproteinuric effects of vitamin D receptor activators. His research on anemia and iron management among patients with CKD is broadly recognized. His foremost contribution has been in the area of hypertension in hemodialysis patients, for which he has been funded continuously since 2003 by the National Institutes of Health. He has refined the techniques to diagnose and treat hypertension in this complex group of patients and has performed important randomized trials in this patient population as well. He serves on the Board of Directors of Kidney Disease--Improving Global Outcomes (KDIGO), has served as a panelist for Medical Evidence Development Coverage Advisory Committee (MEDCAC) for United States Medicare, and most recently contributed a chapter on the approach to the patient with renal disease in Cecil's Textbook of Medicine. He is also a recipient of the Clinical Excellence award from the American Nephrologists of Indian Origin (ANIO).

BACK